866-997-4948 (US-Canada Toll Free)

Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Published By :

Transparency

Published Date : 2015-04-28

Category :

Pharmaceutical

No. of Pages : 104

Product Synopsis


The global peptide therapeutics market report provides detailed analysis, market size, and forecast for therapeutic peptides approved for various indications. The market is studied from four major perspectives: applications, route of administration, marketing status, and geography. Application segments of the global peptide therapeutics market have been further sub-segmented by major branded peptide drugs approved by regulatory authorities across the globe. Various applications considered in the report include metabolic disorders, hematological disorders, cancer, cardiovascular disorders, central nervous system disorders, infection, gastrointestinal disorders, respiratory disorders, acromegaly, and others. Market size and forecast for leading drugs such as Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza, and Zoladex has been included along with in-depth market analysis. Segmentation by marketing status explains the impact of generic drugs on the overall peptide therapeutics market. Further, market segmentation of peptide drugs by route of administration provides quantitative insights into the growing demand for convenient methods for peptide drug administration. Details on peptide drug approvals, patent expiry, mergers, acquisitions, strategic agreements, disease prevalence and other major events have been included in respective market segments.

The global peptide therapeutics market report provides market estimation and forecast for more than fifteen branded peptide drugs in the market. Further, the market is also segmented by major geographical regions, which include North America, Europe, Asia Pacific and Rest of the World. A list of pipeline drugs has also been provided in the report. This list includes potential peptide drugs in phases I, II, and III of clinical development. 

Emerging trends in global peptide API production, such as development of new peptide API production technologies and strategic agreements in peptide API production have been discussed. The report also profiles key peptide API suppliers. An overview of regulatory policies has also been provided in the global peptide therapeutics market report. Based on our in-depth analysis and comprehensive market study, key factors driving and restraining the market have been discussed. A detailed event impact analysis considers regulatory approvals, patent expiry of major drugs, drug recalls and other factors in the peptide therapeutics market.  The research study also incorporates the competitive scenario in these regions, where market share of seven major players in 2013 has also been provided. Relevant recommendations have been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. Fifteen major players have been profiled which include Amgen, Inc., AstraZeneca plc, Bachem Holding AG, CordenPharma International GmbH, Eli Lilly & Co., Ipsen S.A., Lonza, Inc., Merck & Co., Novartis AG, Novo Nordisk A/S, PolyPeptide Group, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. The 104 pages global peptide therapeutics market report includes 30 figures and charts, and 14 tables. 

Market size and forecast in terms of USD million for each segment in the global peptide therapeutics market has been provided for the period 2012 to 2020, considering 2012 and 2013 as the base years. The report also provides the compounded annual growth rate (CAGR %) for each market segment for the forecast period 2014 to 2020. The peptide therapeutics market has been estimated using a bottom-up approach, where market size estimates for each drug have been summed-up to arrive at the total market size. Market forecasts have been derived considering the effect of generic drug approvals, drug recalls, disease prevalence, patent term extension, box warning and various other factors. Inputs from industry experts and key opinion leaders have validated and further refined our market estimates.   

The global peptide therapeutics market has been segmented as below:

Global Peptide Therapeutics Market, by Application
  • Cancer
  • Zoladex (goserelin)
  • Velcade (bortezomib)
  • Lupron/ Enantone/ Eligard (leuprorelin)
  • Others
  • Cardiovascular
  • Angiomax (bivalirudin)
  • Integrilin (eptifibatide)
  • Central Nervous System
  • Copaxone (glatiramer)
  • Metabolic Disorders
  • Victoza (liraglutide)
  • Byetta (exenatide)
  • Others
  • Infection
  • Incivek (telaprevir)
  • Victrelis (boceprevir)
  • Hematological Disorders
  • Firazyr (icatibant)
  • Kalbitor (ecallantide)
  • Gastrointestinal Disorders
  • Gattex (teduglutide)
  • Linzess (linaclotide)
  • Respiratory Disorders
  • Acromegaly
  • Other Applications
Global Peptide Therapeutics Market, by Route of Administration
  • Parenteral
  • Oral
Global Peptide Therapeutics Market, by Marketing Status
  • Branded
  • Generic
Global Peptide Therapeutics Market, by Geography
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Table Of Content


Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations
1.5 Assumptions and Stipulations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
2.2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview
3.1 Introduction
3.2 Emerging Trends in Peptide Therapeutics Market
3.2.1 Trends in Peptide Manufacturing Technology
3.2.2 Trends in Peptide API Supply
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides
3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth
3.3.1.3 Technological advancements have reduced total production cost of peptides
3.3.2 Restraints
3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers
3.3.2.2 Lack of regulatory standards
3.3.3 Opportunities
3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period
3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth
3.4 Regulatory Scenario
3.5 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyer
3.5.3 Threat of Substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Event Impact Analysis
3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
3.8 Market Share Analysis

Chapter 4 Global Peptide Therapeutics Market, by Applications
4.1 Introduction
4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
4.2 Cancer
4.2.1 Global Cancer Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.2.2 Zoladex (goserelin)
4.2.3 Velcade (bortezomib)
4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)
4.2.5 Others
4.3 Cardiovascular
4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.3.2 Angiomax (bivalirudin)
4.3.3 Integrilin (eptifibatide)
4.4 Central Nervous System
4.4.1 Global Central Nervous System Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.4.2 Copaxone (glatiramer)
4.5 Metabolic Disorders
4.5.1 Global Metabolic Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.5.2 Victoza (liraglutide)
4.5.3 Byetta (exenatide)
4.5.4 Others
4.6 Infection
4.6.1 Global Infection Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.6.2 Incivek (telaprevir)
4.6.3 Victrelis (boceprevir)
4.7 Hematological Disorders
4.7.1 Global Hematological Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.7.2 Firazyr (icatibant)
4.7.3 Kalbitor (ecallantide)
4.8 Gastrointestinal Disorders
4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.8.2 Gattex (teduglutide)
4.8.3 Linzess (linaclotide)
4.9 Respiratory Disorders
4.9.1 Global Respiratory Disorders Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
4.10 Acromegaly
4.10.1 Global Acromegaly Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
4.11 Other Applications
4.11.1 Global Other Applications Peptide Therapeutics market  Revenue, 2012 - 2020 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
5.2 Parenteral Route of Administration
5.2.1 Global Peptide Therapeutics Market  Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
5.3 Oral Route of Administration
5.3.1 Global Peptide Therapeutics Market  Revenue, by Oral Route of Administration, 2012 - 2020 (USD Million)

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status
6.1 Introduction
6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
6.2 Branded Peptide Therapeutics
6.2.1 Global Branded Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
6.3 Generic Peptide Therapeutics
6.3.1 Global Generic Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview
7.1 Introduction
7.1.1 Global Peptide Therapeutics Pipeline Overview

Chapter 8 Global Peptide Therapeutics Market, by Geography
8.1 Introduction
8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
8.2 North America
8.2.1 North America Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.3 Europe
8.3.1 Europe Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
8.5 Rest of the World
8.5.1 Rest of the World Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)

Chapter 9 Recommendations
9.1 Rigorous research and development (R&D) would yield new products
9.2 Facility expansion in emerging economies
9.3 Rapid inorganic growth through acquisitions

Chapter 10 Company Profiles
10.1 Amgen, Inc.
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.1.5 Recent Developments
10.2 AstraZeneca plc
10.2.1 Company Overview
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.2.5 Recent Developments
10.3 Bachem Holding AG
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.3.5 Recent Developments
10.4 CordenPharma International GmbH
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.4.5 Recent Developments
10.5 Eli Lilly and Company
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.5.5 Recent Developments
10.6 Ipsen S.A.
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.6.5 Recent Developments
10.7 Lonza Group Ltd.
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.7.5 Recent Developments
10.8 Merck & Co., Inc.
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.8.5 Recent Developments
10.9 Novartis AG
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.9.5 Recent Developments
10.10 Novo Nordisk A/S
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.10.5 Recent Developments
10.11 PolyPeptide Group
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.11.5 Recent Developments
10.12 Roche Holdings AG
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.12.5 Recent Developments
10.13 Sanofi
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.13.5 Recent Developments
10.14 Takeda Pharmaceutical Company Limited
10.14.1 Company Overview
10.14.2 Financial Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.14.5 Recent Developments
10.15 Teva Pharmaceutical Industries Ltd.
10.15.1 Company Overview
10.15.2 Financial Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.15.5 Recent Developments

List of Tables


TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2013 & 2020)
TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market
TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2012 – 2020 (USD Million)
TABLE 4 Global Cancer Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 7 Global Infection Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 8 Global Hematological Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 10 Global Acromegaly Peptide Therapeutics Market  Revenue, 2012 – 2020 (USD Million)
TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2012 - 2020 (USD Million)
TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2012 - 2020 (USD Million)
TABLE 13 Global Peptide Therapeutics Market Pipeline Overview
TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

List of Figures


FIG. 1 Peptide Therapeutics Market Segmentation
FIG. 2 Global Peptide Therapeutics Market, by Applications, 2013 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market
FIG. 4
FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2013
FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2013 (Value %)
FIG. 7 Global Central Nervous System  Peptide Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 10 Global Peptide Therapeutics Market  Revenue, by Parenteral Route of Administration, 2012 - 2020 (USD Million)
FIG. 11 Global Peptide Therapeutics Market  Revenue, by Oral Route of Administration, 2012 - 2020  (USD Million)
FIG. 12 Global Branded Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
FIG. 13 Global Generic Peptide Therapeutics Market  Revenue, 2012 - 2020 (USD Million)
FIG. 14 North America Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 15 Europe Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 16 Asia Pacific Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 17 Rest of the World Peptide Therapeutics Market  Revenue, 2012 - 2020  (USD Million)
FIG. 18 Amgen, Inc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 19 AstraZeneca plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 Bachem Holding AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 22 Ipsen S.A.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 23 Lonza Group Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 24 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 25 Novartis AG Annual Revenue: 2011 – 2013 (USD Million)
FIG. 26 Novo Nordisk A/S Annual Revenue: 2011 – 2013 (USD Million)
FIG. 27 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 28 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2011 – 2013 (USD Million)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Greece: frozen vegetables market

    By - Williams and Marshal Strategy

    ics and structure. The purpose of the report is to describe the state of the frozen vegetables market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market participants, the price fluctuations, the growth and demand drivers of the market and the factors, influencing its development. Last but not least, the...

  • Medical Gas Market - Global Industry Size, Market Share, Trends, Analysis, and Forecasts, 2012 - 2018

    By - Transparency

    Medical gases and pharmaceutical gases are specialized gases used for medical purposes, drug processing and various applications of biotechnology. Medical gases include pure gases and mixture of gases for various medical processes. The major types of gases included in the pharmaceutical and medical gases segment are hydrogen, oxygen, ammonia, boron hydride, nitrous oxide, nitrogen, and carbon dioxide. Technological innovation in the use of medical gases and an increase in demand for better healthcare facilities in developing economies are the major factors which are...

  • Greece: cigarettes market

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the cigarettes market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the cigarettes market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...